In mouse model of NSCLC, the upregulation of TIM-3 was found to be related to anti-PD-1 resistance, and blocking TIM-3 could boost the efficacy of anti-PD-1 therapy 91. Here, HAVCR2 is linked to non-small cell lung carcinoma.